Company Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 10:59:54 2024-04-19 am EDT 5-day change 1st Jan Change
866.2 DKK +0.41% Intraday chart for Novo Nordisk A/S -1.57% +24.08%

Business Summary

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- diabetes and obesity treatment products (92.6%);

- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.

Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Number of employees: 63,845

Sales per Business

DKK in Million2022Weight2023Weight Delta
Diabetes and Obesity Care
92.6 %
156,412 88.4 % 215,098 92.6 % +37.52%
Rare Disease
7.4 %
20,542 11.6 % 17,163 7.4 % -16.45%

Sales per region

DKK in Million2022Weight2023Weight Delta
United States
54.9 %
84,656 47.8 % 127,534 54.9 % +50.65%
EMEA
21.9 %
44,236 25.0 % 50,867 21.9 % +14.99%
Rest of the World
12.1 %
25,402 14.4 % 28,078 12.1 % +10.53%
China
7.2 %
16,209 9.2 % 16,687 7.2 % +2.95%
Canada
3.9 %
6,451 3.6 % 9,095 3.9 % +40.99%

Managers

Managers TitleAgeSince
Chief Executive Officer 58 90-12-31
Director of Finance/CFO 53 98-12-31
Chief Tech/Sci/R&D Officer - 15-09-30
Chief Tech/Sci/R&D Officer 57 17-12-31
Chief Operating Officer 54 91-12-31
Chief Tech/Sci/R&D Officer 54 98-12-31
Investor Relations Contact - 20-02-29
Human Resources Officer 47 06-12-31
General Counsel - -
Corporate Officer/Principal - 20-07-12

Members of the board

Members of the board TitleAgeSince
Director/Board Member 63 15-03-18
Chairman 61 17-03-22
Director/Board Member 68 18-02-28
Director/Board Member 59 17-03-22
Director/Board Member 62 18-02-28
Director/Board Member 57 21-03-24
Director/Board Member 57 21-12-31
Director/Board Member 49 18-03-21
Director/Board Member 52 18-03-21
Director/Board Member 59 22-03-23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 1,075,000,000 0 0 70.47 %
Stock B 1 3,435,000,000 3,178,045,788 ( 92.52 %) 51,700,000 ( 1.505 %)

Shareholders

NameEquities%Valuation
ATP Fondsmaeglerselskab A/S
8.698 %
298,789,780 8.698 % 38 200 M kr
Novo Holdings A/S (Investment Company)
5.536 %
190,183,000 5.536 % 24 315 M kr
48,467,207 1.411 % 6 197 M kr
Pensionskassernes Administration A/S
0.7345 %
25,229,760 0.7345 % 3 226 M kr
PFA Kapitalforvaltning Fondsmæglerselskab A/S
0.6898 %
23,696,970 0.6898 % 3 030 M kr
MP Investment Management A/S
0.5844 %
20,075,914 0.5844 % 2 567 M kr
Swedbank Robur Fonder AB
0.4784 %
16,434,239 0.4784 % 2 101 M kr
Capital International KK
0.2947 %
10,123,000 0.2947 % 1 294 M kr
Universal-Investment-Gesellschaft mbH (Invt Mgmt)
0.2292 %
7,874,764 0.2292 % 1 007 M kr
State Street Global Advisors Ltd.
0.2170 %
7,455,226 0.2170 % 953 M kr
NameEquities%Valuation
Novo Holdings A/S (Investment Company)
100.00 %
1,074,872,000 100.00 % 137 B kr
ANIMA Sgr SpA
0.0129 %
138,860 0.0129 % 18 M kr
Fineco Asset Management DAC
0.009413 %
101,181 0.009413 % 13 M kr
NS Partners SA
0.006408 %
68,876 0.006408 % 9 M kr
Kieger AG
0.002940 %
31,596 0.002940 % 4 M kr
Mercer Global Investments Europe Ltd.
0.002487 %
26,732 0.002487 % 3 M kr
OLZ AG
0.001913 %
20,557 0.001913 % 3 M kr
Union Bancaire Privée, UBP SA
0.001241 %
13,340 0.001241 % 2 M kr
Swissinvest Institut für Angewandte Finanzmarktanalysen GmbH
0.000698 %
7,500 0.000698 % 958 880 kr
DJE Kapital AG
0.000616 %
6,616 0.000616 % 845 860 kr
NameEquities%Valuation
Jennison Associates LLC
0.6558 %
22,527,772 0.6558 % 2 893 M kr
Fisher Asset Management LLC
0.4113 %
14,129,598 0.4113 % 1 814 M kr
Merrill Lynch International
0.4066 %
13,968,876 0.4066 % 1 794 M kr
Renaissance Technologies LLC
0.4032 %
13,849,335 0.4032 % 1 778 M kr
Fidelity Management & Research Co. LLC
0.3686 %
12,663,225 0.3686 % 1 626 M kr
Fayez Sarofim & Co.
0.3439 %
11,814,051 0.3439 % 1 517 M kr
Eaton Vance Management
0.3090 %
10,614,811 0.3090 % 1 363 M kr
Loomis, Sayles & Co. LP
0.2621 %
9,003,325 0.2621 % 1 156 M kr
Folketrygdfondet
0.2549 %
8,756,034 0.2549 % 1 124 M kr
Royal Trust Corp. of Canada
0.2326 %
7,988,697 0.2326 % 1 026 M kr

Holdings

NameEquities%Valuation
48,467,207 1.41% 6,196,562,949 $
4,375,000 17.50% 68,672,756 $
9,817,546 12.14% 23,167,445 $

Company contact information

Novo Nordisk A/S

Novo Allé 1

2880, Bagsværd

+45 44 44 88 88

http://www.novonordisk.com
address Novo Nordisk A/S(NOVO B)

Group companies

NameCategory and Sector
Engineering & Construction
Financial Conglomerates
Pharmaceuticals: Major
Medical/Nursing Services
World Diabetes Foundation
Investment Trusts/Mutual Funds
Velfærdsfonden for Novo Nordisk A/S
Investment Trusts/Mutual Funds
Novo Nordisk Finance (Netherlands) BV
Finance/Rental/Leasing

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
866.2 DKK
Average target price
904.2 DKK
Spread / Average Target
+4.39%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. Company Novo Nordisk A/S